Catalent, Inc. (NYSE:CTLT) Shares Sold by Swiss National Bank

Swiss National Bank reduced its stake in shares of Catalent, Inc. (NYSE:CTLT) by 3.1% in the 4th quarter, HoldingsChannel reports. The firm owned 562,000 shares of the company’s stock after selling 17,900 shares during the quarter. Swiss National Bank’s holdings in Catalent were worth $25,251,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Gladius Capital Management LP purchased a new stake in shares of Catalent during the third quarter worth about $28,000. GAMMA Investing LLC purchased a new stake in Catalent in the 4th quarter worth approximately $33,000. Cary Street Partners Investment Advisory LLC raised its holdings in Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after acquiring an additional 709 shares during the last quarter. Rakuten Securities Inc. purchased a new position in shares of Catalent during the 4th quarter worth $46,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Catalent during the fourth quarter worth $46,000.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. UBS Group reiterated a “neutral” rating and set a $63.50 target price (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Stephens reissued an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. StockNews.com assumed coverage on shares of Catalent in a research note on Sunday. They set a “sell” rating on the stock. Barclays boosted their price objective on shares of Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, February 20th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $52.46.

Catalent Stock Down 0.6 %

NYSE CTLT opened at $56.18 on Thursday. The stock has a market cap of $10.17 billion, a PE ratio of -8.26, a P/E/G ratio of 6.09 and a beta of 1.18. The business has a 50 day moving average price of $56.37 and a two-hundred day moving average price of $49.31. Catalent, Inc. has a fifty-two week low of $31.45 and a fifty-two week high of $60.20. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. Catalent’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.62 earnings per share. As a group, sell-side analysts predict that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.